Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Welcome to the Vivian Group Q3 2024 report. For the first part of the conference call, the participants will be in listen-only mode. During the questions and answers session, participants are able to ask questions by dialing Pound Key five on their telephone keypad. Now I will hand the conference over to the speakers, CEO Patrick Erickson and CFO Karl Johan Zetterberg. Boundary. Please go ahead.
Thank you very much. Good morning, and thank you for joining our third quarter earnings call. I'm going to jump straight into it today and maybe look at some of the highlights from the third quarter. We continue to exhibit double-digit organic growth and margin expansion in the quarter. We had strong adjusted EBITDA growth, and we improved our cash flow from our operations. And we passed an important milestone when we entered into an adjacent and additional MedTech niche by acquiring a business in the veterinary dentistry space. I want to go through a little bit more in detail on what was driving these results. So first of all, 10% organic revenue growth. And it's driven by our Specialty Pharma and our MedTech and Veterinary Services segments, which both showed very strong growth. And our adjusted EBITDA grew by 20% and ended up being 21.9 million. Our EBITDA margin came in at 25% year-over-year, and that’s also an improvement. If we turn to our Specialty Pharma segment, we see strong growth here with 13%. We experienced very strong growth across all of our therapeutic areas. As you know, we've discussed our growth initiative. The one focus point to drive organic growth is our cross-selling initiative. And that initiative alone yielded one third of the growth. The positive margin development seen in Specialty Pharma is driven by a continued focus on integrating our acquisitions and optimizing the business overall. And the adjusted EBITDA grew by 24% in this part of our business. If we then turn to MedTech, the organic growth in this segment was 4%. And it's driven by factors that make it slower than in Q2. It's driven by softness in the U.S. high-cost surgical elective market, specifically in areas like knees and hips. And today, we don't see any sign of recovery in this part of the segment. In our European and APAC businesses, we had continued high single-digit growth. The margin improvement here is driven by the annual order program, where we have now flattened out our sales of those products across each quarter, which has evened out our margin profile over the quarters and the years as well. Um, our initiative to drive growth in MedTech is all about capturing the white space. We do that mostly by way of education and conducted over 20 on-site educations with almost 300 participants in the third quarter; our adjusted EBITDA for MedTech grew by 19%. We then switch over to our veterinary services business. Um, very strong growth here of 17%, and we see positive momentum across all of our key geographies in the business. Our initiative for growth in veterinary services, as you know, is all centered around acquiring new members, and we added 250 new clinics to our membership, for a total of 8,200. At the end of the quarter, margins were up substantially here. And it's really because of our higher penetration of services among existing customers. And we're seeing good benefits from the scale that this business is now starting to drive. And the EBITDA growth for veterinary services came in at 34%, which is an exceptional growth rate for this business. Now turning to our fourth and last segment. Diagnostics business accounts for about 5% of our total business, and we continue to see a decline in this segment by 5%. The end markets here, which focus on livestock, have unchanged characteristics. The profitability in this business is lower because we have launched a parasitology test for the companion animal sector, where we are refocusing and diversifying this segment of our business into companion animals. And we'll continue that effort in the future as well. And with that said, maybe we can switch over to discussing the acquisition we just completed. We're very excited about having completed the iM3 acquisition. Um, it's a global leader in the veterinary dental space. Just as a reminder of our strategy, we've said that the M&A strategy involves adding products or geographies into our existing platforms in Specialty Pharma, MedTech, or Veterinary Services. We also said that we're looking for new therapeutic areas for Specialty Pharma and MedTech. And this is precisely a new therapy area for our MedTech business. We're excited to have acquired the global leader in the veterinary dental space. iM3 has very strong brand recognition in this niche. The niche grows very fast and has very high customer satisfaction. And as we've said before. But just as a reminder, this acquisition would add about $7.7 million in EBITDA, and we consolidated the business into our operations here on October 1st this year. We wanted to look a little bit closer at the company. It's a family-owned business that was founded in Australia about 30 years ago. That has been a very, very successful endeavor. Um, customers in over 40 countries selling both directly and through distribution. We're adding 85 employees to the family and welcome them to our company. And we have offices in the US, Australia, Ireland, and the UK. And just like we have in our orthopedics business, whitespace capture and education are key drivers for growth here. iM3 has a number of state-of-the-art education centers that can be used for both dental and orthopedic education. So, we're very excited to add more capabilities here. If we look at additional acquisitions in this segment, we are looking at driving acquisitions that will help us improve and increase the margin profile of the business. That includes consumables businesses and distribution businesses that will help us achieve that. If we look at our product portfolio in here, we have some very specialized dental units, X-ray units, instruments that are used for the actual surgical or dental procedures, some small equipment, services, and consumables. So today, about 32% of the revenue from this business is of a recurring nature. So with that said, I'm going to end my piece here and hand over to Carl-Johan to walk us through a little bit more details on the financials. Over to you. Carl. Carl-Johan.
Thank you very much, Patrick. And I said, let's take a more detailed view of the financials for the third quarter. Adjusted EBITDA in the third quarter was €21.9 million, at a margin of 25.0%. This is a solid improvement from 22.9% for the same quarter last year, supported by positive margin development in all of our three largest segments. We see effects from cross-selling, benefiting from scale as well as mix. We report an operating profit of €10.1 million, a year-over-year growth of 2%. Items affecting comparability clearly impacted the operating profit in the quarter. In total, the items affecting comparability amounted to €6.5 million, with costs for the iM3 acquisition as well as continued high level of legal costs for the US patent litigation. The net financial items of -€9.3 million consist of three main elements. Finance expense of -3.8 million, with an average interest rate of 6.0% in the quarter, offset by 0.5 million interest income. The quarterly discounting impact amounted to -€1.2 million, with an additional impact of €0.1 million from probability adjustments on contingent considerations. And lastly, a negative impact of 5 million from unrealized effects. Effects on revaluation of debt. The income tax expense for the quarter amounted to €2.7 million. In total, this results in a net profit for the quarter of -€1.9 million. The negative result is a consequence of the high amount of items affecting comparability, as well as a negative impact from effects on the net financial items. Q3 cash flow. Cash flow from operating activities reached 16.7 million in the third quarter. An improved cash generation compared to the same period last year, as well as to the second quarter of this year. Net working capital amounted to €80.8 million at the end of the quarter, equal to 23% of revenue, a decrease from €82.0 million at the end of June, which equals 24% of revenue. We see opportunities to gradually improve working capital and cash flow over time. During the quarter, we further improved our processes for inventory management across the group, and as a consequence, the decrease in net working capital of €1.1 million compared to the end of the second quarter is driven by the decrease in inventory in MedTech and lower accounts receivables as MedTech AOP customers pay their monthly installments. The decrease was to some extent offset by slightly lower accounts payable. Cash flow from investing activities of -€89.2 million primarily reflects the timing effect from financing the iM3 acquisition, payable on October 1st. Cash flow from financing activities of 70.7 million, with the proceeds of the rights issue in the second quarter of 142.7 million, has been used to repay 142.4 million of debt, partially offset by the new loan of €78.5 million for the iM3 acquisition. At the end of the period, net debt amounted to 140.3 million, down from 144.1 million at the end of the second quarter. External lending totaled €240.1 million. Following the repayment of the proceeds from the rights issue, as well as the use of funds to finance the iM3 acquisition. Leverage in the quarter equaled 1.3X, compared to 1.4X at the end of the second quarter. With this financial review of the quarter, I would like to hand the word back to Patrick for concluding remarks before we open up for the Q&A session. Thank you very much.
Carl, do you want. So, just in conclusion here, if we look at this. Now we are delivering a quarter with double-digit growth. We continue to see margin expansion. We improved our cash flow in the third quarter. We have our focus on the US surgical market, which continues to be very soft. And we'll continue to deploy various commercial actions and monitor the situation here for the future. The long-term growth drivers in this industry are very clear and strong. The humanization of pets, the elderly population of pets as well, because they live longer, and also the ability to treat our companion animals when they get sick are great, healthy growth drivers that will continue to show good, solid growth for the future here. And our near-term priorities are all centered around organic growth. Continue our operational improvements and drive to really make this the best place to work, ensuring that we successfully onboard our recent acquisition, iM3, and continue to advance our M&A pipeline and agenda. With that said, I'd like to open up for Q&A. Thank you very much.
If you wish to ask a question, please dial pound five on your telephone keypad. To enter the queue. If you wish to withdraw your question, please dial pound six on your telephone keypad. The next question comes from Rikard Andersson from Handelsbanken. Please go ahead.
Good morning, and thank you for taking my questions. So, the first set of questions concerns the growth and expectations for iM3 over the five-year earnout period here. Is it reasonable to assume, you know, about a 10% organic growth for the business over that period? And does your full earnout imply, you know, plus 25% EBITDA CAGR, which is in line with the development of the acquired companies you presented in conjunction with updated targets earlier this year? So start there. Thank you.
Thank you. Good morning. Thank you for your question. Um, when we look at iM3, you know, the margin is at 21.5% and we think that the EBITDA margin for the business is going to grow over time. And we do that by way of operational improvements, by considering additional acquisitions that have recurring higher margins, and also potentially acquiring some of the distribution channels that are available there. And all those three together will kind of move the margin up to a higher level on the growth rates. We saw healthy growth in iM3 in the third quarter, and we can continue to see how iM3 will grow at about the average of what we see today. The niche is growing very fast. I think we can capitalize on it, and we feel very good about how that can add to the value creation of our company going forward.
All right. Perfect. And as a follow-up, since you're set to pay earnouts for the deal, do you expect to generate meaningful excess free cash flow from the business to fund new acquisitions if we adjust for the earnouts as well?
So on that note, we see good opportunities for solid cash generation from iM3, our dental business within MedTech. As discussed when we announced iM3, there are two portions of the earnouts: one is a hurdle earnout, which we believe is very likely to achieve the projected earnings. And then, as Patrick mentioned, there's a second earnout option for the sellers. That would imply very strong performance for us at iM3. And if those earnouts are payable, then very strong cash generation will also be achieved by the business.
All right. And what's the rough split between the hurdle and the optionality based on performance?
So the first earnout payment on the hurdle is 10 million. And then the optionality in the full amount is 50 million. If they achieve the full second tranche of the Earnout.
Very, very clear. Thank you so much for that. And on the weak outlook for MedTech in the US. You mentioned not really seeing any improvements in the short term, but looking at the industry data from the US, there seems to have been a 7% growth year over year in the market in September. Was that just a blip in the curve, or have you seen deterioration in October? It would be interesting to hear a bit more on what you're seeing. And yes, the underlying development there. Thank you.
Yeah. Thank you. That's a good question. As you know, that same data source you're looking at shows minus one and minus one. And year to date it's -1.3. So it could be a blip in the curve in September. Of course, it would be great if it wasn't. But I think it's too early to call it out. And if you look at the monthly variation of that number, it is quite volatile. So although it could be the beginning of a turnaround, we don't want to suggest that it is. Let's look at October and November and get a few more months. And if that pattern is prevailing, then I think we are in the turnaround. But I think it's too early to call at this point.
All right, fair enough, fair enough. And just a final question. Any update on the oversight of the launch in the diagnostics business? When can we expect to see top-line impact there and recovering margins back to double digits? Should we assume double-digit margins for diagnostics in 2025, or would it be interesting if any sort of flavor on the outlook there would be very helpful?
So, on the sort of companion animal launch within diagnostics. And as we communicated in previous quarters, we've taken a conscious decision to invest in the go-to-market strategy for the companion animal diagnostics solutions that we have. And as you rightly pointed out, that has had a negative impact on the margins for 2024. And we continue to see that for the rest of the year. The companion animal launch is progressing, and we are observing an uptick in the companion animal business, despite launching a new technology. It takes time to achieve market uptake, even though we are seeing some positive momentum, and it involves a razor-razorblade model where we'll continue to see a recurring revenue stream as more machines are installed. With that said, this will be a continuous journey where we'll start to see improving sales and improving margins over time. And it will not be a step change. It will be a gradual improvement for diagnostics and for the companion animal solutions over time.
All right. So, single-digit growth should probably continue for a few more quarters. Then we should probably assume single-digit levels.
We should assume that we will see a slight but steady improvement in margins, as both the companion animal business is likely to continue to show positive momentum even though, as we said, we're making this go-to-market investment now for the full year, and we will conduct a very close evaluation at the beginning of next year to see. So what's the next step in our companion animal diagnostic solutions and how do we take that to market? And then, of course, it depends on how our livestock business performs as well, because that's the largest part of our diagnostic segments. And we see that we have healthy margins within our core livestock diagnostics business. So as both continue to develop, hopefully positively during next year, we will see gradually more margin improvement quarter over quarter.
Okay. That's helpful. Thank you for taking my questions.
The next question comes from Marco Cox from Barclays. Please go ahead.
Hi there. Good morning. Thank you for taking my question. I have two questions, please. So firstly, just on the US MedTech business, obviously weakness here started last quarter, and we are still seeing some weakness there. I'm just curious whether you have any visibility on the ground when it comes to iM3 and the dental business there, given that peers in the overall dental market have reported weakness in the US market for quite some time. So I'm just curious to see whether you're seeing weakness in iM3 as well as in the US MedTech business. And then, secondly, just a quick one on Specialty Pharma. You know, one third of the organic growth year to date comes from cross-selling. I just wonder, how are you thinking about this over the long run? Do you think this is a reasonable basis to continue, or do you expect to be able to expand this to be a higher contribution to organic growth over time? Thank you.
Thank you for your questions. We'll start with the first one. When it comes to potential softness in the dental business in the US, we don't see it, as we don't see it in the downturn business. We see it in the high-end elective surgical procedures. So, knees and hips in the US orthopedic business. On the specialty pharma piece, the cross-selling initiative has a long runway. We're still at the beginning of that initiative. We've acquired 20 businesses in Specialty Pharma and most of them have a characteristic where it's been a local company with its own manufacturing that has had local sales, or sold in that country and adjacent countries. And we're making those product portfolios truly international as part of this cross-selling initiative. And you should also consider that any additional acquisitions we make in Specialty Pharma will be integrated into the cross-selling initiatives, serving as part of the synergies in any such acquisition. So, you know, I think this initiative has a very long runway.
Perfect. Thank you.
The next question comes from Arvid Nikander from Carnegie. Please go ahead.
Good morning and thanks for taking my questions. So first off, on iM3, consensus seems to expect the underlying market to rebound in 2025. And I'm assuming that it does. How confident are you that iM3 will achieve double-digit growth this year? Um, do you see any risk of this, for example, with temporary loss of customers as you convert distributor markets to direct markets or any other factors? And secondly, on orthopedics, do you believe there will be any sort of meaningful pent-up demand once the market fully rebounds? I'll start there. Thank you.
Okay. Thank you, Arvid, for your question. So the first one is on iM3. We're not planning to make many radical changes initially, so I don't anticipate any shifts in our customer base or any other significant changes. And I think that the primary focus for us in iM3 is all about accelerating organic growth and ensuring that now iM3 is part of a bigger family, we can leverage the scale and capabilities we have together to be stronger. And so I would expect iM3 growth rates to increase and improve over time. And the second question about pent-up demand for orthopedics, and it's a possibility that that might happen. And, you know, if you need a knee or a hip on a dog, there's a certain window where it's economically feasible to actually perform that surgery. If you wait too long, I think you leave that window. If the market rebounds here in very short order, I think there could be a positive rebound. But if this is a longer period. I'm not sure there's going to be a rebound because those animals will be outside the window where it's, you know, defensible to actually go through those relatively expensive surgeries.
Great. Thank you. And just the last one, if I may. Consensus. Consensus doesn't seem to expect any major margin dilution for MedTech in 2025, assuming a full market rebound. How hopeful are you that you can improve the margin for iM3 already in 2025? It doesn't seem like you're planning many near-term initiatives there, but yes, conversion of distributor markets to direct markets, and increased focus on consumables or other initiatives. Any color there would be helpful. Thanks.
Yeah. Good. And maybe I'll get back to your questions and maybe just to fill in on what Patrick said. On to the US. Rather than the market, we see opportunities for iM3. I think it's important to remember as well. And as we communicated when we entered the dental space with the acquisition of iM3, there is a great reason why we're entering this space and why we see a very long-term avenue for growth, because this is a segment with a lot of white space that we see. So even if there would be a slower market or, as you asked, in terms of changing to going direct from distributors. Etcetera. We see a lot of white space to cover within the dental business, and it is a huge opportunity for vets to increase their offerings within dental as well as for them to develop and grow their business. Then, to your question on margins for iM3. So we have a very strong long-term belief that we can continue to develop our dental business with very solid growth and margin expansion, to, over time, bring them to the fleet average of the group. And this we will do step by step, very consciously ensuring that we improve margins, looking to develop and invest in the business long-term to ensure that we capture white space and drive growth. That will, of course, mean that margins will improve over time. But we are investing in the business for the long term. We are investing in the business to ensure that, especially from a financial and governance perspective, we meet the requirements of the main market listed company. So that is weighing a little bit on the cost level. And as a consequence, the margin for iM3 and MedTech dental. But with that said, we are positive that we will continuously improve margins in MedTech Dental over time to bring them to a fleet average from a group perspective.
Great, thanks. Those are all my questions.
The next question comes from Sten Gustafsson from ABG Sundal Collier. Please go ahead.
Good morning. Uh, if you could go back to the US MedTech market, and I'm sorry if you already covered this in your prepared remarks. Um, which I missed. Partly, but would it be possible to split up the market into elective surgical procedures and more trauma, and talk about the performance and how the acute or trauma market is developing? And also, if you could share with us the growth rate in the EU and the rest of the world for the MedTech business, that would be helpful.
Yeah. Yeah.
Thank you. Good morning, Stan. And then we'll start with the second part of your question. The Europe and APAC business is growing high single digits, and the North America business grew 1%. Yeah. So that's the kind of growth division. And we internally split the growth rates for the elective and non-elective procedures. So if you look at fracture plates, which are typically non-elective, if you've had trauma and you break a leg, you will put fracture plates on there. The volume of fracture plates is very steady. The volume involving knees and hips, particularly knees, is much higher than hips. That's where we see the volume decrease, as a result, I think, of people electing to do those surgeries either later or postpone them indefinitely. And I think that was a different question about that. It's hard to speculate whether they're going to rebound or if those opportunities are lost. But we do see that the trauma-related business is very steady. And the knee business is where we see the market impact, with people delaying those surgeries today.
Excellent. And sort of share of the sales roughly. Are we talking 50-50 or is it an 80-20 split between the elective and non-elective in a typical year or so?
Uh, Stan, that's a great question. I actually don't know the exact split on that. Um.
We can get back to you on the exact details of how we split. No, I don't know the exact split or how it will look for different products in terms of whether they're elective or more trauma-based. I think that's a different way of slicing it. We can get back to you on that. Uh, still on that.
Yes.
Okay.
And then finally, a general question on pricing for MedTech globally. Is that positive year over year, or?
Yeah. Yeah.
Does that price typically work? Yeah.
Global price is up 5%. Global prices are up 5%. The price increases that we conducted in the past. Yeah.
And do you expect to be able to raise prices for next year as well?
Yeah, probably, but not at that same level. The increases would be smaller. If we deploy that.
Okay. Thank you very much. That's all for me.
The next question comes from Kavya from UBS. Please go ahead.
Good morning. Thank you for taking my questions. I've got two questions, please. The first is, again, on us. MedTech. I was just curious to understand how you're thinking about next year in terms of your commercial strategy, given what you're seeing. Do you expect to conduct another annual ordering program next year? Would it be downsized? Will it be for similarly small sizes as this year? Um, yeah. So that's on that. And then on Specialty Pharma, I was wondering if you could share whether the cross-selling initiatives are concentrated in certain therapeutic areas and brands. And then also, if I could have another question on Specialty Pharma on a regional basis, it looks like there were some shifting dynamics here. So sequentially it looks like Europe is obviously still very strong in double digits, but possibly stepped down compared to last quarter. And North America steps up sequentially versus last quarter. So, are there any dynamics to flag there, in terms of where the products are launching, and where the integration efforts are concentrated regionally? That would be helpful. Thank you.
Thank you very much. I'll start by answering your first two questions. I'll let Karl Johan answer the third question you had. So the first question was related to MedTech. And whether we see an AOP program coming next year, we reduced the AOP program quite significantly this year, in the first quarter, but there are still customers who prefer to do AOP programs.
They will continue to do so in the first quarter.
They will continue to do so in the first quarter. So I expect there to be a level of an AOP program. It might be a little bit smaller again in Q1. Um, which I would guess means we might have a few more customers switching over to either monthly or quarterly ordering programs. Regarding your second question about the Specialty Pharma segment on cross-selling, could you elaborate on what the team is doing there? There are 15 distinct cross-selling initiatives inside that segment, and they span multiple geographies and therapeutic areas. So, it's a little bit all over the board, which is probably a good answer to that. But there are additional things you can add into the cross-selling. Going back to the other question here about how much runway there is. So, there's significant runway in the program. And Carl, maybe you want to take the third part of the question, which is the regional dynamics.
Yeah.
So, regarding your question about cross-selling, one of the reasons we see continued runway for this strategy within Specialty Pharma is predominantly in allergy and dermatology. We're starting to see other initiatives that are sort of bearing fruit in other therapeutic areas as well, indicating further potential for growth going forward. And that's why we see this as a long-term opportunity.
Sort of long-term opportunity.
And runway to drive continued growth in Specialty Pharma and the regional dynamics. And, as you mentioned, the growth in the US and perhaps.
Of North America versus Europe between the two quarters, there are two sort of main things to keep in mind in that one.
Between North America and Europe over the two quarters, there are two main factors to consider. In Q2, we had very strong sales in our specialized pharmaceuticals business, especially in Europe and the UK, where one of our competitors was struggling, and we had a great opportunity to go in and capture business. So we had a very strong performance in specialized pharmaceuticals in the second quarter, which sort of increased our share of sales in revenue. And we also experienced slightly slower growth in our specialized nutrition business, which is predominantly based in North America, specifically the US. So the mix effect is driving the performance variations in different regions between the quarters. In this quarter, we've seen a sort of uptake in growth in specialized pharmaceuticals, taking a larger share of sales, which also has a mixed impact on the margin. If we look.
Sort of.
Sequentially, Q2 to Q3. And secondly, there's a seasonal effect as well. We had a very strong month-over-month quarter in Europe in Q2. It's slightly slower in Q3, and that's largely due to a seasonal effect from the summer period in Europe.
Understood. Thank you. That's very clear.
The next question comes from Rikard Andersson from Handelsbanken. Please go ahead.
Hi. Just a quick follow-up. So, I know the UK is quite an important market for the Vivien group. There was another company in this space that pointed out the larger vet chains have been somewhat cautious in the UK, potentially due to the antitrust investigation ongoing in the market there. So I just wanted to kick the tires and see if that's any concern or risk that you're seeing, or if you felt anything that you wanted to double-check. Thank you.
Uh, no. And as you say, we're monitoring that event closely. Of course, we may also see some actions from the larger corporates in the UK. They have needed to take action based on this ongoing investigation. From our perspective, we see continued good momentum in the UK. And we have a very diversified customer base and various routes to the market in the UK. So we haven't seen any real impact from this. And as we've communicated before, we're welcoming this investigation and making sure that we do what's best for pet parents.
All right. Perfect. Thank you so much for taking my questions.
As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no more questions at this time, so I hand the conference back to the speakers for any closing comments.
Well, thank you very much. Thanks for your attention and interest today. Um, again, double-digit growth in Q3, margin improvement, and improvement in our cash flow generation. We do see an impact from our US surgery business, as we've discussed here. However, we are confident that we will finish the year with healthy, full-year, solid growth. And we are looking forward to meeting you again when we report the fourth quarter and the full year. Take care and have a wonderful day. Now.



















